Pravastatin is one of the safer statins when it comes to drug interactions, but “safer” does not mean “free of risk.” Several medications can sharply raise pravastatin levels in the blood or compound its side effects, particularly its tendency to cause muscle damage. The most dangerous combination is pravastatin with cyclosporine, which can nearly quadruple drug exposure. Other problematic pairings include gemfibrozil, clarithromycin, certain HIV medications, and colchicine, each for somewhat different reasons. Because pravastatin avoids the liver enzyme pathway that trips up most other statins, its interaction profile is distinct enough that some drugs dangerous with simvastatin or atorvastatin are perfectly fine with pravastatin, and vice versa.
Why Pravastatin’s Interaction Profile Differs From Other Statins
Most statins are broken down by a liver enzyme family called CYP450, particularly the CYP3A4 variant. Any drug that blocks CYP3A4 can cause those statins to accumulate to dangerous levels. Pravastatin sidesteps this problem almost entirely because it is not significantly processed by CYP450 enzymes.1PubMed. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans Instead, the body handles pravastatin mainly through glucuronidation (a different chemical process) and through transporter proteins in the liver and kidneys. The two key transporters are OATP1B1, which pulls pravastatin into liver cells, and MRP2, which pushes it into bile for excretion.
This means pravastatin’s danger zone is different. Drugs that block those transporter proteins, or that interfere with glucuronidation, are the ones that cause trouble. A classic CYP3A4 inhibitor like grapefruit juice, which dramatically raises simvastatin levels, has little meaningful effect on pravastatin. But a drug like cyclosporine, which hammers the OATP1B1 transporter, hits pravastatin hard even though pravastatin is supposedly the “gentler” statin. Understanding this distinction matters because patients and even some clinicians assume that pravastatin’s reputation for fewer interactions means they can combine it freely with anything. That is not true.
Cyclosporine Is the Highest-Risk Combination
Cyclosporine is an immunosuppressant used after organ transplants and in some autoimmune conditions. When taken with a single 40 mg dose of pravastatin, cyclosporine raised pravastatin’s blood exposure by roughly 282%.2Journal of Clinical Lipidology. Management of statin drug-drug interactions: An expert clinical consensus document That is nearly four times the normal level. The interaction is not driven by CYP enzymes but by cyclosporine’s ability to block multiple transport systems at once, including OATP1B1 and possibly intestinal efflux proteins.2Journal of Clinical Lipidology. Management of statin drug-drug interactions: An expert clinical consensus document
For transplant patients who need both cholesterol management and immunosuppression, this is a real clinical problem. The elevated pravastatin levels increase the risk of rhabdomyolysis, a condition where muscle fibers break down and release their contents into the bloodstream, potentially damaging the kidneys. If pravastatin is used at all alongside cyclosporine, it requires a much lower dose and close monitoring. Some guidelines recommend starting at the lowest available pravastatin dose and capping it well below the usual maximum.
Gemfibrozil and the Fibrate Question
Fibrates are another class of lipid-lowering drugs often prescribed alongside statins for patients with high triglycerides. But not all fibrates carry the same risk. Gemfibrozil is the problematic one. It interferes with the glucuronidation process that pravastatin depends on for clearance, raising statin levels in the blood and increasing the chance of muscle toxicity.3PubMed Central. Fibrates in combination with statins in the management of dyslipidemia Gemfibrozil also blocks the renal transporter OAT3, creating a double hit: the liver clears less pravastatin, and the kidneys do too.2Journal of Clinical Lipidology. Management of statin drug-drug interactions: An expert clinical consensus document
Fenofibrate, by contrast, does not interfere with statin glucuronidation or pharmacokinetics in any clinically meaningful way.4PubMed. Combination statin-fibrate therapy: safety aspects That difference translates directly into fewer cases of muscle injury. When patients need both a statin and a fibrate, fenofibrate or fenofibric acid is the recommended choice.5Nature Reviews Endocrinology. Myopathy with statin–fibrate combination therapy: clinical considerations This is not a theoretical preference; it reflects a consistent pattern across clinical reports and pharmacokinetic studies. If you are currently taking gemfibrozil with pravastatin, that combination deserves a conversation with your prescriber about switching the fibrate.
Clarithromycin and Erythromycin
Clarithromycin is a macrolide antibiotic commonly prescribed for respiratory infections, sinus infections, and as part of treatment regimens for stomach ulcers caused by H. pylori. It is one of the stronger CYP3A4 inhibitors, which is why it causes dramatic spikes in simvastatin and atorvastatin levels. With pravastatin, the effect is smaller but still significant: clarithromycin roughly doubles pravastatin’s blood exposure.6PubMed. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors For context, clarithromycin increased simvastatin’s exposure roughly tenfold in the same study, so pravastatin is far less affected, but a twofold increase is still enough to matter.
The pravastatin manufacturer recommends that the dose not exceed 40 mg per day when taken with clarithromycin.7Journal of Translational Science. An updated review of interactions of statins with antibacterial and antifungal agents Erythromycin, another macrolide antibiotic, carries a similar caution and was listed as a contraindicated co-therapy in at least one clinical trial protocol involving pravastatin.8PubMed Central. Safety and Pharmacokinetics of Pravastatin Used for Preventions of Preeclampsia in High-Risk Pregnant Women: A Pilot Randomized Controlled Trial The practical takeaway: if you are prescribed a short course of clarithromycin or erythromycin while on pravastatin, your doctor may temporarily hold the statin or reduce the dose for the duration of the antibiotic course. If the antibiotic will be used for a longer period, a different antibiotic without this interaction, such as azithromycin, may be substituted instead.
Itraconazole, a common antifungal and another potent CYP3A4 inhibitor, does not significantly affect pravastatin levels.7Journal of Translational Science. An updated review of interactions of statins with antibacterial and antifungal agents This is one of the areas where pravastatin’s non-CYP metabolism genuinely gives it an advantage. Patients on long-term antifungal therapy who need a statin may be steered toward pravastatin precisely because of this favorable profile.
HIV Antiretroviral Drugs
HIV treatment often involves protease inhibitors boosted with ritonavir or cobicistat, drugs known to wreak havoc on CYP3A4-dependent statins. Simvastatin and lovastatin are considered flat-out contraindicated with most HIV protease inhibitor regimens. Pravastatin is generally considered acceptable, but the picture is more complicated than a simple green light.
Darunavir boosted with ritonavir increased pravastatin exposure by about 81% after a single dose, though the increase settled down to about 23% at steady state. The recommendation is to start with the lowest necessary pravastatin dose and monitor closely.9PubMed Central. Evidence-based review of statin use in patients with HIV on antiretroviral therapy Lopinavir/ritonavir raised pravastatin levels by about a third, which generally does not require a dose adjustment. Saquinavir/ritonavir, oddly, did the opposite: it decreased pravastatin exposure by about 50%, potentially making the statin less effective rather than more dangerous.9PubMed Central. Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz tend to induce pravastatin metabolism, reducing its effectiveness. Efavirenz decreased pravastatin exposure by about 40%, which could mean your cholesterol is not being adequately treated even though you are taking the statin as prescribed.9PubMed Central. Evidence-based review of statin use in patients with HIV on antiretroviral therapy The general principle with HIV protease inhibitors is to start any statin at the lowest dose and titrate carefully.10PubMed. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors A case of rhabdomyolysis was reported in a patient taking pravastatin with fenofibrate and a cobicistat-boosted protease inhibitor regimen, a reminder that stacking multiple interacting drugs compounds the risk even when each individual pairing seems manageable.9PubMed Central. Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Colchicine and Kidney Function
Colchicine, used for gout flares and certain inflammatory conditions, can cause muscle toxicity on its own. Combined with pravastatin, the risk of serious muscle problems increases, particularly in people with even mild kidney impairment.11PubMed. Acute myopathy in a patient with concomitant use of pravastatin and colchicine Case reports have documented acute myopathy in patients using both drugs together when kidney function was not fully normal.
That said, large-scale adverse event data from the FDA’s reporting system suggest that the combination of pravastatin specifically with colchicine carries only a minimal increase in the risk of rhabdomyolysis compared to some other statins paired with colchicine.12PubMed Central. Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug–drug interactions through the FDA adverse event reporting system The risk is not zero, but pravastatin appears to be on the lower end of the statin spectrum for this particular interaction. The key variable is kidney function: because both colchicine and pravastatin depend partly on renal clearance, any reduction in kidney performance lets both drugs accumulate. If you take colchicine regularly and your doctor is aware of your kidney health, the combination can often be managed. If kidney function declines or if you start a new medication that further stresses the kidneys, the equation changes.
Hepatitis C Antivirals
Direct-acting antivirals for hepatitis C have their own interaction profile with statins. Boceprevir, an older protease inhibitor used in hepatitis C treatment, increased pravastatin exposure by about 63%.2Journal of Clinical Lipidology. Management of statin drug-drug interactions: An expert clinical consensus document Newer hepatitis C regimens have largely replaced boceprevir, but the principle remains relevant because many direct-acting antivirals interact with OATP1B1 and other transporters that govern pravastatin levels. If you are starting hepatitis C treatment while on pravastatin, your hepatologist or infectious disease specialist should review the specific regimen for transporter-mediated interactions, even though pravastatin avoids the CYP3A4 problems that make simvastatin and lovastatin off-limits in this setting.
Bile Acid Sequestrants and Timing
Cholestyramine and colestipol are older cholesterol-lowering drugs that work by binding bile acids in the gut. They are sometimes used alongside statins for additional cholesterol reduction. The issue is not a metabolic interaction but a physical one: these resins bind to many orally taken drugs in the intestine, preventing them from being absorbed. If you swallow pravastatin at the same time as cholestyramine, much of the statin may never reach your bloodstream. The standard guidance is to take pravastatin at least one hour before or four hours after the bile acid sequestrant. Following this timing rule eliminates the problem entirely.
Niacin at Prescription Doses
High-dose niacin (the prescription form, not the small amounts in a daily multivitamin) is another lipid-modifying agent that has been combined with statins. Both niacin and statins independently carry a risk of muscle injury, and combining them adds those risks together. Niacin was listed among the contraindicated co-therapies in at least one clinical trial’s exclusion criteria for pravastatin use.8PubMed Central. Safety and Pharmacokinetics of Pravastatin Used for Preventions of Preeclampsia in High-Risk Pregnant Women: A Pilot Randomized Controlled Trial Prescription niacin has fallen out of favor in recent years because large trials showed it added cardiovascular risk without providing a clear benefit when added to statin therapy. Still, some patients take it, and the additive muscle toxicity risk is worth knowing about.
When Genetics Raise the Stakes
Drug interactions do not happen in a vacuum. Some people are more vulnerable to elevated pravastatin levels because of inherited differences in the transporter proteins that move the drug through the body. Variations in the SLCO1B1 gene, which encodes the OATP1B1 transporter, can reduce that transporter’s activity. A person with a less efficient OATP1B1 transporter already has higher baseline pravastatin levels, so adding an interacting drug on top pushes them further into dangerous territory.13PubMed. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins
Some patients also carry pre-existing subclinical muscular conditions that make them more susceptible to statin-related muscle damage in general.14PubMed. The genetics of statin-induced myopathy These individuals may tolerate pravastatin alone but develop symptoms when an interacting drug is added. Pharmacogenomic testing for SLCO1B1 variants is available and increasingly used in clinical practice, though it is far from routine. If you have experienced muscle problems on statins in the past, or if you take several medications that interact with the OATP1B1 pathway, asking about this testing is reasonable.
Drugs That Are Typically Fine With Pravastatin
Given that most of this article covers what to avoid, it is worth noting what does not cause problems. Many of the classic CYP3A4 inhibitors that are dangerous with simvastatin and atorvastatin are not an issue for pravastatin. Itraconazole, as mentioned, does not significantly raise pravastatin levels.7Journal of Translational Science. An updated review of interactions of statins with antibacterial and antifungal agents Calcium channel blockers like diltiazem and verapamil, which require dose caps for simvastatin, generally do not pose the same issue with pravastatin. Amlodipine, another common blood pressure medication, is similarly unproblematic. Grapefruit juice, which gets an outsized share of statin-interaction anxiety, has no clinically relevant effect on pravastatin.
This relatively clean profile is exactly why pravastatin is often the statin of choice for patients on complex medication regimens, including organ transplant recipients on lower doses of immunosuppressants, people living with HIV, and elderly patients taking multiple drugs. The trade-off is that pravastatin is a moderate-intensity statin, meaning it does not lower LDL cholesterol as aggressively as high-dose atorvastatin or rosuvastatin. For some patients, its interaction safety advantage outweighs its somewhat weaker cholesterol-lowering power.
Red Yeast Rice and Other Supplements
Red yeast rice supplements contain monacolin K, which is chemically identical to lovastatin. Taking red yeast rice alongside pravastatin is essentially taking two statins at once, with all the compounded muscle risk that implies. The supplement industry does not standardize monacolin K content reliably, so you cannot know exactly how much extra statin exposure you are getting. If you are using red yeast rice for additional cholesterol lowering while on pravastatin, you should tell your prescriber so the combined effect can be accounted for.
Coenzyme Q10 (CoQ10) is sometimes taken by statin users in the hope of reducing muscle side effects. It does not interact with pravastatin in a pharmacokinetic sense, and evidence for its ability to prevent statin myopathy is mixed. St. John’s wort, an herbal supplement used for mild depression, induces certain drug-metabolizing enzymes and transporters. While its primary effect is on CYP3A4, it can also affect transporter activity, potentially reducing pravastatin’s effectiveness. Patients on any statin should disclose all supplements, including herbals, to their prescriber.
When Multiple Interacting Drugs Stack Up
The most dangerous scenarios tend to involve not a single drug interaction but a pile-up. A patient on pravastatin, colchicine, and a moderate CYP3A4 inhibitor, or a patient on pravastatin, gemfibrozil, and an HIV protease inhibitor, faces compounding risks that are harder to predict from studying each pair individually. The case of rhabdomyolysis in a patient taking pravastatin plus fenofibrate plus a cobicistat-boosted protease inhibitor illustrates this.9PubMed Central. Evidence-based review of statin use in patients with HIV on antiretroviral therapy Each individual combination might have been manageable; together, they crossed a threshold.
Kidney function acts as a multiplier in these situations. Pravastatin is partly cleared by the kidneys, and many of its interacting drugs (colchicine, cyclosporine, some antivirals) also depend on renal clearance. A modest decline in kidney function that would be clinically insignificant on its own can become the factor that tips a borderline drug combination into toxicity. If you take pravastatin alongside any of the drugs discussed here and your kidney function changes, even slightly, a medication review is warranted. The same applies to acute illness, dehydration, or any situation that temporarily reduces kidney performance.